Platelet Rich Fibrin can last longer than PRP due to the slow release of growth factors

Global Interstitial Cystitis & Bladder Pain Syndrome (IC/BPS) Treatment Market Size, and Share, By Treatment Type (Oral Pharmacotherapy, Intravesical Therapy, Neuromodulation Devices, Biologics & Emerging Therapies, and Others), By Disease Type (Non-Hunner IC/BPS, Hunner Lesion IC/BPS, and Refractory IC/BPS), By End User (Hospitals, Specialty Urology Clinics, Ambulatory Surgical Centers, Research Institutes, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2026 - 2035 Industry: Healthcare Global Interstitial Cystitis & Bladder Pain Syndrome (IC/BPS) Treatment Market Insights Forecasts to 2035 The Global Interstitial Cystitis & Bladder Pain Syndrome (IC/BPS) Treatment Market Size Was Estimated at USD 0.94 Billion in 2025 The Market Size is Expected to Grow at a CAGR of around 8.11% from 2026 to 2035 The Worldwide Interstitial Cystitis & Bladder Pain Syndrome (IC/BPS) Treatment Market Size is Expected to Reach USD 2.05 Billion by 2035 Asia Pacific is expected to grow the fastest during the forecast period
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
Storage: Store the unmixed vial at -20C
Cholesterolosis indicates the accumulation of lipid cholesterol droplets in the mucosa of the gallbladder wall